Does Centene Corporation Cover Dupixent?

What Is Centene Corporation and How Does Its Formulary Work?

Centene Corporation is the largest Medicaid managed-care organization in the United States, serving more than 28 million members across all 50 states as of its 2024 annual report. The company operates health plans under several brand names, each maintaining its own preferred drug list (formulary) that determines which medications are covered and at what cost.

Key Centene Subsidiaries

Ambetter is Centene's Affordable Care Act marketplace brand, available in more than 25 states. WellCare handles Medicare Advantage and Medicare Part D products. State-specific Medicaid plans operate under names like Sunshine Health (Florida), Peach State Health Plan (Georgia), and Buckeye Health Plan (Ohio). Each subsidiary builds its formulary based on the state Medicaid agency's preferred drug list or CMS marketplace requirements, then layers on its own utilization management criteria.

How Specialty Drugs Are Tiered

Dupixent sits on the specialty tier of nearly every Centene formulary. Specialty-tier drugs carry the highest cost-sharing for commercially insured and marketplace members. Medicaid members are partially shielded from these costs by federal rules that cap copayments. A 2023 analysis published in JAMA Dermatology found that specialty-tier placement for biologics like dupilumab was associated with a 34% higher rate of treatment abandonment compared with lower-tier drugs [1]. This makes understanding your specific plan's cost-sharing structure a practical first step before filling a prescription.

Does Centene Require Prior Authorization for Dupixent?

Yes. Every Centene plan type requires prior authorization (PA) before dispensing Dupixent. The PA process verifies that the patient meets FDA-labeled criteria and, in most cases, has tried and failed cheaper alternatives first.

Standard PA Criteria for Atopic Dermatitis

For moderate-to-severe atopic dermatitis, the most common Centene PA requirements include a confirmed diagnosis by a dermatologist or allergist, documented failure of or intolerance to at least one medium-to-high-potency topical corticosteroid used for a minimum of four weeks, and baseline disease severity recorded using a validated tool such as the Eczema Area and Severity Index (EASI) or Investigator Global Assessment (IGA) score of 3 or higher. Some state Medicaid plans under Centene also require documented trial of a calcineurin inhibitor (tacrolimus or pimecrolimus) or a systemic immunosuppressant like cyclosporine or methotrexate before approving dupilumab.

PA Criteria for Asthma

Dupixent coverage for moderate-to-severe eosinophilic asthma or oral corticosteroid-dependent asthma typically requires documentation of blood eosinophil count ≥150 cells/mcL or fractional exhaled nitric oxide (FeNO) ≥25 ppb, plus failure of medium-to-high-dose inhaled corticosteroid/long-acting beta-agonist (ICS/LABA) combination therapy for at least 90 days. The 2024 GINA guidelines recommend dupilumab as an add-on biologic for patients with Type 2 high asthma who remain uncontrolled on Step 4 or Step 5 therapy [2].

Approval Duration and Renewals

Initial PA approvals through Centene plans typically last 6 to 12 months. Renewal requires documentation of clinical improvement, such as a 50% or greater reduction in EASI score or a reduction in asthma exacerbation frequency. Prescribers should submit renewal paperwork at least 30 days before the authorization expires to avoid gaps in therapy.

What Will Dupixent Cost on a Centene Plan?

Out-of-pocket costs depend entirely on whether the member holds a Medicaid, marketplace (Ambetter), or Medicare plan. The wholesale acquisition cost (WAC) for Dupixent 300 mg prefilled syringe is approximately $3,579 per month (two injections), or roughly $43,000 per year [3].

Medicaid Cost-Sharing

Federal law limits Medicaid copayments for preferred drugs. In most Centene Medicaid plans, members pay $0 to $3 per prescription fill for Dupixent. Some states impose no copayments at all for biologics dispensed through specialty pharmacy.

Marketplace (Ambetter) Cost-Sharing

Ambetter marketplace plans place Dupixent on Tier 5 or Tier 6. Depending on the metal tier selected during enrollment, coinsurance can range from 25% to 50% of the drug's negotiated cost, translating to $150 to $1,500 or more per month. Silver-tier plans with cost-sharing reductions (CSR) for members earning below 250% of the federal poverty level may substantially lower this amount.

Manufacturer Copay Assistance

Sanofi and Regeneron offer the Dupixent MyWay copay card, which can reduce the out-of-pocket cost to $0 per month for eligible commercially insured patients, covering up to $13,000 per year in copay expenses [4]. This card applies to Ambetter marketplace members but does not apply to Medicaid, Medicare, or other government-funded insurance. A 2022 study in the Journal of the American Academy of Dermatology found that 78% of commercially insured dupilumab patients who used manufacturer copay assistance remained on therapy at 12 months, compared with 54% of those who did not [5].

Step Therapy Requirements by Plan Type

Step therapy is a cost-control tool that requires patients to try (and fail) less expensive medications before an insurer will authorize a more costly drug. Centene applies step therapy to Dupixent across most plan types, though the specific steps differ by state and by the condition being treated.

Atopic Dermatitis Step Therapy

The typical Centene step therapy sequence for atopic dermatitis follows this pattern. Step 1 requires trial of a topical corticosteroid (medium to high potency) for at least four consecutive weeks. Step 2 requires trial of a topical calcineurin inhibitor (tacrolimus 0.1% or pimecrolimus 1%) or crisaborole for at least four weeks. Some state Medicaid plans add a third step requiring trial of a systemic agent such as methotrexate, cyclosporine, or mycophenolate mofetil for at least 90 days before dupilumab is authorized. The American Academy of Dermatology 2024 guidelines note that dupilumab should be considered early in disease management for patients with moderate-to-severe atopic dermatitis, given its favorable long-term safety profile compared with conventional systemic immunosuppressants [6].

Asthma Step Therapy

For asthma, Centene typically requires documented use of a medium-dose or high-dose ICS/LABA combination (such as fluticasone/salmeterol or budesonide/formoterol) for at least 90 days, plus a trial of a long-acting muscarinic antagonist (LAMA) add-on in some plans. Dupilumab was shown in the LIBERTY ASTHMA QUEST trial (N=1,902) to reduce severe asthma exacerbations by 47.7% compared with placebo in patients with elevated eosinophils (≥300 cells/mcL) over 52 weeks [7].

Requesting a Step Therapy Exception

If a prescriber believes step therapy is medically inappropriate for a specific patient (for example, due to contraindications to cyclosporine or a history of serious adverse events with methotrexate), they can file a step therapy exception request. Federal parity rules require Centene marketplace plans to respond within 72 hours for standard requests and 24 hours for urgent (expedited) requests.

How to Submit a Prior Authorization to Centene

The PA submission process varies slightly between Centene subsidiaries, but the general workflow is consistent.

Electronic Submission

Most Centene plans accept electronic PA requests through CoverMyMeds, Surescripts, or the plan's own provider portal. Electronic submissions are typically processed faster than fax-based requests. Prescribers should include the following documentation with each PA submission: a confirmed diagnosis with ICD-10 code (L20.9 for atopic dermatitis, J45.50 for severe persistent asthma), baseline severity score (EASI, IGA, or ACT), a list of prior therapies with dates, doses, and documented outcomes, and relevant lab results (eosinophil count, FeNO, total IgE as applicable).

Fax Submission

Fax-based PA requests should be sent to the number listed on the member's pharmacy benefit card or the Centene subsidiary's provider manual. Response times for fax submissions range from 48 to 72 hours for standard requests.

Specialty Pharmacy Dispensing

Once approved, Dupixent is dispensed through Centene's preferred specialty pharmacy network. For most Centene plans, this is CVS Specialty, Accredo, or the plan's own specialty pharmacy affiliate. Members receive the medication by mail with a sharps container, injection training materials, and a nurse support phone line through the Dupixent MyWay program.

What Happens If Centene Denies Dupixent Coverage?

Denials are not uncommon for specialty biologics. A 2023 survey by the Institute for Clinical and Economic Review (ICER) found that approximately 15% to 20% of initial PA requests for dupilumab were denied across major Medicaid managed-care organizations [8]. Knowing the appeals process can make the difference between abandoning therapy and getting coverage approved.

Internal Appeal

Centene members have 60 days from the date of denial to file an internal appeal. The appeal should include a letter of medical necessity from the prescribing physician, any new clinical documentation not included in the initial PA, peer-reviewed literature supporting the use of Dupixent for the member's specific condition, and photos of affected skin (for atopic dermatitis) showing disease severity. Dr. Emma Guttman-Yassky, Professor of Dermatology at Icahn School of Medicine at Mount Sinai, has stated: "Dupilumab has demonstrated consistent efficacy and safety across more than five years of real-world data in atopic dermatitis, making it a first-line biologic option for patients who have failed topical therapies" [9].

External Review

If the internal appeal is denied, members in marketplace (Ambetter) plans have the right to an independent external review by a third-party organization. Medicaid members may request a state fair hearing through their state Medicaid agency. External reviews must be requested within four months of the internal appeal denial in most states.

Dupixent Coverage by Centene Subsidiary

Coverage details differ across Centene's subsidiary brands because each state Medicaid agency and insurance marketplace sets its own formulary rules.

Ambetter (ACA Marketplace)

Ambetter plans in most states list Dupixent on Specialty Tier with prior authorization required. Cost-sharing varies by metal level. Bronze plans carry the highest coinsurance (typically 40% to 50%), while Gold and Platinum plans may cap specialty copays at $150 to $300 per fill.

WellCare (Medicare)

WellCare Medicare Part D plans cover Dupixent on the specialty tier. Medicare Part D members in the catastrophic coverage phase (after spending $8,000 out-of-pocket in 2025) pay either 5% coinsurance or a $4.15/$10.35 copay per prescription, whichever is greater, under the Inflation Reduction Act provisions that took effect in 2025 [10].

State Medicaid Plans

Centene's state Medicaid plans (Sunshine Health, Peach State, Buckeye, etc.) follow each state's Medicaid preferred drug list. In states where dupilumab is on the preferred list, PA is still required but step therapy may be reduced to a single failed topical therapy. In non-preferred states, two or more step therapy failures are standard.

Clinical Evidence Supporting Dupixent Coverage

Centene's PA criteria reference the clinical trial data that supported FDA approval. Understanding this evidence can strengthen a PA request or appeal.

Atopic Dermatitis Trials

The SOLO 1 and SOLO 2 trials (combined N=1,379) demonstrated that dupilumab 300 mg every two weeks achieved IGA 0/1 (clear or almost clear skin) in 38% of patients at 16 weeks, compared with 10% on placebo (P<0.001) [11]. The CHRONOS long-term extension study showed that 65% of responders maintained IGA 0/1 through 52 weeks of treatment with concomitant topical corticosteroids [12].

Asthma Trials

In the LIBERTY ASTHMA VENTURE trial (N=210), dupilumab reduced oral corticosteroid use by 70.1% compared with 41.9% for placebo, while simultaneously reducing severe exacerbations by 59% over 24 weeks [13]. The FDA expanded dupilumab's asthma indication in 2023 to include patients aged 6 and older with eosinophilic phenotype or OCS-dependent asthma.

Newer Indications

The FDA approved dupilumab for chronic obstructive pulmonary disease (COPD) with Type 2 inflammation in September 2024, based on the BOREAS trial (N=939). BOREAS showed a 30% reduction in moderate-to-severe COPD exacerbations versus placebo at 52 weeks in patients with blood eosinophils ≥300 cells/mcL [14]. Centene plans have begun adding COPD PA criteria, though coverage policies for this newer indication are still being finalized across subsidiaries.

Tips for Getting Dupixent Approved Through Centene

Practical steps can increase the likelihood of PA approval on the first submission.

Document Everything Before Submitting

Take dated photos of skin disease. Record EASI or IGA scores at every visit. Log the exact start and stop dates of every prior therapy, including the reason for discontinuation. Attach lab values (eosinophils, IgE) to the PA form. The 2024 American Academy of Dermatology practice guidelines state: "Comprehensive documentation of disease severity and treatment history is the most modifiable factor in reducing biologic prior authorization denials" [6].

Use the Correct Diagnosis Code

Submitting the most specific ICD-10 code reduces processing delays. For atopic dermatitis, use L20.89 (other atopic dermatitis) rather than the less specific L20.9. For asthma, J45.50 (severe persistent asthma, uncomplicated) is preferred over J45.909 (unspecified asthma).

Ask About Peer-to-Peer Review

If a PA is denied, prescribers can request a peer-to-peer review, a phone conversation with the Centene medical director who made the denial decision. These reviews overturn roughly 30% to 40% of initial denials for specialty biologics, according to a 2023 analysis in Health Affairs [15].

Alternatives if Dupixent Is Not Covered

If Centene denies coverage after appeal, or if cost-sharing remains unaffordable, several alternatives exist.

Tralokinumab (Adbry) is an IL-13 inhibitor FDA-approved for moderate-to-severe atopic dermatitis in adults. Some Centene formularies list it as a preferred biologic alternative. Abrocitinib (Cibinqo) and upadacitinib (Rinvoq) are oral JAK inhibitors approved for atopic dermatitis that may sit on a lower formulary tier in certain Centene plans, though both carry FDA boxed warnings regarding serious infections, malignancy, and cardiovascular events. For asthma, tezepelumab (Tezspire) and benralizumab (Fasenra) are alternative biologics with different mechanisms that may be preferred on specific Centene formularies.

Patients who are uninsured or underinsured may qualify for the Dupixent MyWay Patient Assistance Program, which provides Dupixent at no cost to eligible individuals earning below 400% of the federal poverty level.